Celexi

Quick links to important sections

Celexi

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Celexi

What is Celexi? A Foundational Overview

Celexi is a prescription-only medicine whose active component is Celecoxib. It is chemically a synthetic compound classified as a selective cyclooxygenase-2 (COX-2) inhibitor, a subgroup of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), used for general relief of pain and inflammation.

Property Description
Active ingredient Celecoxib
Form Hard capsule, Oral solution
Pharmacological class Selective COX-2 Inhibitor (Coxib)
Common use Relief of pain and inflammation
Origin Synthetic, small molecule

What Type of Medicine is Celexi (Celecoxib)?

Celexi (Celecoxib) is an NSAID belonging to the pharmacological subgroup known as the coxibs, defined by its precise mode of action. Celecoxib is used to manage symptoms arising from various types of chronic and acute pain and inflammation. This medicine helps ease discomfort by providing relief from the general symptoms of pain and swelling.

Unlike traditional NSAIDs, which non-selectively affect multiple enzymes, Celecoxib is a selective inhibitor of the COX-2 enzyme. This selectivity is its key pharmacological characteristic, differentiating it from non-selective analogues by focusing on the enzyme primarily associated with inflammation.


Composition, Form, and Origin

The product contains a single active ingredient, Celecoxib, which is a synthetic small molecule chemically defined as a diaryl-substituted pyrazole with a sulfonamide moiety. This composition gives the drug the necessary structure to specifically bind to the target enzyme in the body. Celecoxib is not extracted from natural sources but is produced through chemical synthesis.

Celexi is formulated for the oral route of administration and is typically supplied as a hard capsule. In some markets, it is offered as an oral solution variant, providing an alternative for patients who may have difficulty swallowing capsules.


General Purpose and Targeted Relief

The general purpose of Celexi is to utilize its selective inhibition to provide systematic pain relief and anti-inflammatory activity, managing the generalized symptoms of stiffness and swelling. Its use is recognized for managing pain associated with general joint stiffness, providing consistent symptomatic control. The fundamental benefit is the targeted suppression of prostaglandins, the local chemical messengers that propagate the sensation of pain and initiate inflammatory responses.

What side effects are possible with Celexi?

Possible Side Effects and Safety Information

As a selective COX-2 inhibitor, Celexi (Celecoxib) is associated with safety characteristics documented in official regulatory sources. The medicine is associated with risks of serious cardiovascular (CV) thrombotic events, including myocardial infarction (heart attack) and stroke, which may increase with the duration of use and can occur early in treatment. It is also linked to serious gastrointestinal (GI) adverse events, such as bleeding, ulceration, and perforation, which can occur without warning symptoms.

Adverse reactions are classified by frequency, generally reflecting the expected rate of occurrence in clinical use:

  • Common: Effects reported frequently include hypertension (high blood pressure), peripheral oedema (swelling), dyspepsia (indigestion), abdominal pain, and upper respiratory tract infection.
  • Less Common/Rare: Effects involving systems such as the cardiac, hepatic, and renal systems are documented at lower frequencies. Very rarely, serious skin reactions, including Stevens-Johnson syndrome (SJS), have been reported.

Official Safety Constraints

The medicine is subject to regulatory constraints and is contraindicated (absolutely prohibited) in certain situations. It must not be used for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery. It is also contraindicated in patients with a history of sulphonamide allergy or allergic-type reactions, such as asthma or hives, after taking aspirin or other NSAIDs.

Population-specific safety statements advise against use in pregnant women starting at 30 weeks of gestation due to the risk of fetal harm. Older adults are noted to have a greater risk for serious GI and renal adverse events.

Overdose and Emergency Response

Celexi Overdose and When to Seek Help

The official regulatory profile for Celexi (Celecoxib) overdose documents specific clinical manifestations and mandates clear emergency actions. Symptoms commonly reported in an overdose situation include lack of energy, drowsiness, nausea, vomiting, and stomach pain. Regulatory information emphasizes that overdose is associated with the potential for effects on the gastrointestinal system, such as bleeding, and the renal system, including acute failure, which are key concerns that guide supportive management.

Overdose Status Official Regulatory Actions
Common Presentation Call the poison control helpline and seek immediate medical attention.
Life-Threatening Risk Immediately call emergency services (911) if the person has collapsed, had a seizure, has trouble breathing, or can't be awakened.

Management must focus on providing symptomatic and supportive care, as the official regulatory labeling confirms that no specific antidote is known for a Celecoxib overdose. Procedural interventions such as activated charcoal may be considered if administered within four hours of ingestion following a large exposure. Due to the potential for severe outcomes, clinical monitoring and observation are required. This approach reflects the standardized framework used by regulatory authorities for managing Nonsteroidal Anti-Inflammatory Drug toxicity.

Therapeutic Uses of Celexi

What Celexi Treats: Main Uses and Benefits

Symptomatic Relief for Chronic Joint Inflammation

Celexi is commonly applied across conditions characterized by periods of heightened symptoms and symptoms related to inflammatory or irritative states, such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). For children two years of age and older, it is considered relevant for managing the symptoms of Juvenile Rheumatoid Arthritis (JRA). It helps address the core symptom cluster of joint stiffness, swelling, and tenderness. This therapeutic effect supports patients during episodes of heightened discomfort and contributes to improved comfort during symptomatic periods. The primary indications are: Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, acute pain, and Primary Dysmenorrhea.

“It is commonly used across domains where additional symptomatic support is needed, and is relevant for easing symptoms that interfere with daily comfort.”

Management of Acute Pain and Episodic Discomfort

This medication is commonly used when symptoms related to physical discomfort appear suddenly or fluctuate, such as acute pain following trauma or surgical procedures. It is also applied in addressing the disruptive, recurrent manifestations of Primary Dysmenorrhea (painful menstrual periods). These are situations where symptoms create noticeable physiological strain. It is applied in scenarios where additional management of discomfort is required and may assist with helping patients cope more steadily with symptom fluctuations during difficult, acute episodes.


Quick Fact: Relief for Joint Stiffness and Pain Celexi supports the patient during episodes of heightened discomfort by addressing symptoms that create noticeable functional strain in conditions marked by episodic or fluctuating manifestations.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Celexi (Celecoxib)

Official regulatory sources specify clear restrictions on who can and cannot use Celexi. Use is contraindicated (prohibited) for patients with a known hypersensitivity to celecoxib, any component of the formulation, or a known allergy to sulfonamides. The medicine must also not be used if a patient has a history of allergic-type reactions (such as asthma or hives) after taking aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), or for treating peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Population Group Eligibility Status (Regulatory)
Pediatric Patients Use established for children geq 2 years of age for Juvenile Rheumatoid Arthritis; use not established for those younger than 2 years.
Severe Hepatic Impairment Not recommended (Child-Pugh Class C).
Severe Renal Impairment Avoid use or use is not recommended.
Pregnancy geq 30 Weeks Avoid use due to risk of premature closure of fetal ductus arteriosus.
Lactation/Breastfeeding Can be used; human data shows no known risk of infant harm.

Older adult patients do not have a general eligibility restriction but require caution due to an increased risk of serious gastrointestinal and cardiovascular events. Patients with moderate hepatic impairment require a 50% dose reduction for use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Celexi (Celecoxib) has officially documented interaction patterns that are classified primarily based on effects on drug metabolism and pharmacodynamic risk.

Documented Pharmacokinetic Interactions

The most significant metabolic interaction involves the Cytochrome P450 2C9 (CYP2C9) enzyme pathway. Co-administration with the strong CYP2C9 inhibitor Fluconazole is documented to result in a two-fold increase in Celecoxib plasma concentration and total exposure. Conversely, drugs that induce CYP2C9 (e.g., Rifampin) may compromise Celecoxib's effectiveness. Celecoxib also has the potential to inhibit CYP2D6, which may increase the exposure of medicines metabolized by this enzyme.

Pharmacodynamic Risk and Exposure Changes

Official regulatory sources note that co-administration with Warfarin or other oral anticoagulants carries an increased risk of serious bleeding events. This additive risk also applies when combined with SSRIs, SNRIs, or Antiplatelet Agents. Furthermore, Celecoxib can reduce the natriuretic and antihypertensive effects of Diuretics, ACE Inhibitors, and ARBs. Celexi also affects the renal clearance of specific medicines, documented to increase serum concentrations of co-administered Lithium and Digoxin.

Administration Constraints

Use is formally contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other non-aspirin NSAIDs is strongly advised against. While not mandatory, co-administration with aluminum- and magnesium-containing antacids is documented to reduce Celecoxib's maximum plasma concentration (Cmax). Administration can occur without regard to the timing of meals, although a high-fat meal can delay absorption.

Mechanism of Action

Selective COX-2 Inhibition and Prostanoid Suppression

The mechanism of Celecoxib is centered on the selective inhibition of the Cyclooxygenase-2 ( COX-2) enzyme. By preferentially binding to this molecular target, the drug blocks the early stages of the Prostanoid Biosynthesis Pathway, significantly reducing the formation of key lipid mediators like Prostaglandin E2 ( PGE2). This targeted interference with the enzyme initiates a cascade that modulates the generation of specific pro-inflammatory mediators.

️ Integrated Central and Peripheral Pathway Modulation

The drug's mechanism modulates activity across peripheral tissues and central regulatory systems. In local tissues, the mechanism suppresses the prostanoids that heighten nociceptor sensitivity and increase vascular permeability. Concurrently, the inhibition of PGE2 synthesis in the brain’s hypothalamus alters the body’s thermal set point. This integrated action results in simultaneous modulation across the nociceptive and thermoregulatory pathways.

Dosage and Administration Information

How to Use Celexi: Administration Guidelines

Celexi (celecoxib) is a medication administered via the oral route, available as a hard capsule in strengths including 50 mg, 100 mg, 200 mg, and 400 mg, or as an oral solution. Use is guided by instructions which emphasize utilizing the lowest effective dosage for the shortest duration possible.


Standard Dosing and Frequency

Standard adult dosing depends on the condition being addressed and may be taken once or twice daily, or on an as-needed basis for acute episodes.

Condition Typical Dosing Regimen
Osteoarthritis (OA) 200 mg once daily or 100 mg twice daily
Rheumatoid Arthritis (RA) 100 mg to 200 mg twice daily
Acute Pain 400 mg initial dose, followed by 200 mg as needed on Day 1; 200 mg twice daily thereafter

For most conditions, the total daily dose should generally not exceed 400 mg. For conditions such as Ankylosing Spondylitis, the therapeutic benefit is assessed after a six-week trial.


Administration Context and Adjustments

Celexi capsules can be taken with or without food. For patients who cannot swallow the capsule whole, the contents may be sprinkled onto a level teaspoon of applesauce, rice gruel, yogurt, or mashed banana and must be ingested immediately with water.

Specific dosage adjustments are noted for certain populations. For example, the daily dose should be reduced by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). For children 2 years of age and older with Juvenile Rheumatoid Arthritis, the dose is weight-based.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Celexi

Evidence for Chronic Joint Conditions (Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis)

This section will summarize the structure of the extensive research conducted using Randomized Controlled Trials (RCTs) and meta-analyses to examine the assessment of chronic inflammatory joint conditions in adult populations.

Research examining Osteoarthritis (OA) and Rheumatoid Arthritis (RA) involves RCTs and controlled clinical trials. These studies were used in research exploring how outcomes related to physical discomfort and daily functioning might change over defined time intervals. Findings describe patterns observed in these studies where measurements of pain and physical function scores changed over the study period. For Ankylosing Spondylitis (AS), clinical trials have also been conducted, although the overall volume of evidence is documented as being less extensive than that available for OA and RA.

Evidence for Acute, Episodic Pain Management

This part will detail the types of short-term clinical trials that evaluated patients with sudden-onset discomfort, such as acute pain following procedures and the episodic discomfort associated with Primary Dysmenorrhea.

Clinical evaluation of Celexi was also conducted for indications involving acute or disruptive episodes. Studies monitored outcomes describing episodic or acute changes. Findings are specific to temporary, sudden symptom phases and do not provide data on long-term functional outcomes or sustained symptom stability for other types of chronic pain. A key research limitation here is the focus on very short follow-up durations.

Evidence in Special Populations (Juvenile Arthritis and Older Adults)

The clinical evaluation of Celexi was conducted for Juvenile Rheumatoid Arthritis (JRA) / Juvenile Idiopathic Arthritis (JIA) in children aged two years and older. Research in this group often faces inherent limitations, including modest sample sizes and a reliance on short observation periods. The data for certain pediatric groups remain insufficient, and the relationship between age, weight, and systemic exposure was a documented topic of discussion in regulatory reviews.

What is Still Uncertain in the Research Landscape

Despite the body of research, certain elements remain under exploration. Comparative evidence regarding the speed of symptom change in various acute pain models is sometimes lacking or inconsistent across studies. Additionally, in the context of chronic conditions, ongoing discussions concern the long-term comparative outcomes against traditional NSAIDs, particularly for patients with specific comorbidities and baseline characteristics documented in the research. Regulatory documents have noted that the evidence quality varies across studies.

Frequently Asked Questions (FAQ)

Common questions about Celexi (FAQ)

Q: How quickly should a person expect to notice any effects from Celexi?

A: Regulatory pharmacokinetic data indicates that the active ingredient, celecoxib, is rapidly absorbed after being taken orally. The concentration of the medicine in the blood typically reaches its peak in about three hours. This describes the speed at which the substance becomes available in the body.


Q: Is it common to feel tired after starting Celexi?

A: While not listed as a commonly occurring effect, excessive tiredness or unusual weakness is noted in official documentation as a potential serious side effect. Official documents state that symptoms such as excessive tiredness require immediate medical evaluation.


Q: Does Celexi cause weight changes?

A: Unexplained weight gain or swelling (edema) of the feet and ankles is documented as a symptom of a potential serious adverse event. Official regulatory guidance notes that symptoms such as unexplained weight gain require immediate medical evaluation.


Q: Is Celexi an addictive substance?

A: No, the active ingredient in Celexi, celecoxib, is a type of Nonsteroidal Anti-Inflammatory Drug (NSAID). According to regulatory classifications, it is not considered a narcotic or a controlled substance.


Q: What are the official warnings about taking Celexi with alcohol?

A: Official warnings indicate that combining this medication with alcohol consumption can significantly increase the risk of serious stomach issues. This additive risk includes the potential for gastrointestinal problems like ulcers and bleeding.


Q: Does the time of day a person takes Celexi matter?

A: The official administration context indicates that the capsule form can generally be taken without regard to the timing of meals. The prescribed frequency is noted in the administration context.


Q: Are there any restrictions on driving or operating machinery while using Celexi?

A: While there are no general restrictions, some less common side effects are documented that have been reported to potentially impair ability to operate machinery. These include symptoms like dizziness, drowsiness, and blurred vision.


Q: What should a person do if they experience a mild side effect from Celexi?

A: Official guidance distinguishes between mild and serious symptoms. Official guidance suggests that patients inform their healthcare provider if mild effects (such as gas or constipation) become persistent or severe. For serious symptoms (e.g., breathing difficulty, unexplained weight gain), official guidance indicates that they require immediate medical evaluation.


Q: Can Celexi cause problems with sleep?

A: Inability to sleep (insomnia) is listed in regulatory documentation as a more common side effect of celecoxib. Drowsiness or sleepiness is also sometimes reported as an adverse event.


Q: Are there any specific lifestyle changes that are recommended while taking Celexi?

A: Official warnings primarily focus on documented risks. However, documented risks for gastrointestinal bleeding are noted to increase with the use of alcohol and smoking. It is noted that these factors should be discussed with a healthcare professional.


Q: Why do some official documents mention a Boxed Warning for Celexi?

A: Official documents include a Boxed Warning to highlight the serious potential risks associated with the medicine. This warning specifically addresses the increased possibility of serious cardiovascular thrombotic events (like heart attack and stroke) and serious gastrointestinal adverse events (like bleeding and perforation).


Q: Is it normal to feel a mild headache when first starting Celexi?

A: Yes, headache is listed in the official documentation as one of the more common side effects that patients may experience while using this medication.


Q: Is Celexi a type of narcotic or controlled substance?

A: Celexi, whose active component is celecoxib, is categorized as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It has not been classified as a narcotic or a controlled substance by regulatory authorities.


Q: Is it possible to take too much Celexi?

A: Regulatory reports indicate that taking too much can result in an overdose. Symptoms that have been documented include drowsiness, nausea, vomiting, and severe headache. The management of overdose involves supportive and symptomatic care.


Q: Can Celexi affect laboratory test results?

A: Official product labeling contains a section on Laboratory Tests. This section notes that anemia (low red blood cell count) may occur during treatment. Monitoring of specific lab values is often noted as a consideration for patients on long-term therapy.


Q: Is there a generic version of Celexi available?

A: Yes, regulatory agencies, such as the FDA, have approved a generic version of the active ingredient, celecoxib. The availability of a generic alternative is based on the single active component.


Q: Are there any official reports of Celexi causing vision changes?

A: Blurred vision is listed as a less common side effect in official reports. There are documented instances of visual disturbances that have been associated with the use of the medicine.

How should Celexi be stored and disposed of?

How to Store and Dispose of Celexi (Celecoxib)

Entity Regulatory Requirement
Storage Temperature Store at Controlled Room Temperature between 20 C to 25 C (68 F to 77 F); excursions permitted up to 30 C [1, 2].
Packaging Rules Must be kept in the original container [5].
Child Safety Must be stored out of the sight and reach of children [5, 6].
Stability after Mixing Capsule contents mixed with applesauce, rice gruel, or yogurt are stable for up to 6 hours under refrigerated conditions (2 C to 8 C) [3, 4].
Disposal Dispose of unused or expired product according to local regulations [6]. The FDA recommends using a drug take-back program or following specific household trash disposal steps [7].

Regulatory documents define that Celexi must be stored within a specific temperature range defined as Controlled Room Temperature, prohibiting environments outside of the maximum limit of 30 C. Official labeling specifies the product must be protected from child access and kept in the original container. Handling and in-use stability are documented for cases where capsule contents are mixed with certain foods, providing conditional storage limits for those mixtures before they must be administered or discarded [1, 3].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Celexi found in:

A-Z Index: